Oral News and Research

RSS

New findings on cystic fibrosis-related diabetes

A growing number of cystic fibrosis patients are battling a second, often deadly complication: a unique form of diabetes that shares characteristics of the type 1 and type 2 versions that strike many Americans.

10 Jul 2006

Celiac success: New enzyme efficiently degrades gluten

A new enzyme originally developed for commercial food processing turns out to also quickly and nearly-completely break down whole gluten molecules as well as the T cell stimulatory peptides that cause celiac disease, a digestive disease with no current effective treatment other than avoiding wheat, barley or rye products.

5 Jul 2006

New method of jaw reconstruction for oral cancer patients

Mayo Clinic ear, nose and throat surgeons have developed a promising new process for mandible (lower jaw) reconstruction following removal of oral cancer.

29 Jun 2006

FDA grants accelerated approval for Sprycel (dasatinib)

FDA grants accelerated approval for Sprycel (dasatinib), a new oral treatment for patients with chronic myeloid leukemia (CML),

29 Jun 2006

FDA gives tentative approval for generic pediatric AIDS drug

The Food and Drug Administration (FDA) today announced the tentative approval of the generic version of Abacavir Sulfate Oral Solution.

27 Jun 2006

Simple test for HIV for all of Washington DC

Washington DC has the the highest rate of new HIV and AIDS cases in the U.S.

26 Jun 2006

FDA warns of possible risks to children using Triaminic Vapor Patch

The U.S. Food and Drug Administration (FDA) today is warning consumers not to use the Triaminic Vapor Patch marketed by Novartis Consumer Health due to reports of serious adverse events associated with accidental ingestion by children.

19 Jun 2006

Chlorhexidine decreases risk of acquiring hospital-related ventilator-associated pneumonia

Researchers found that administering the topical antiseptic chlorhexidine to critically ill patients on mechanical ventilation greatly decreased their daily risk of acquiring deadly hospital-related ventilator-associated pneumonia.

18 Jun 2006

Safe for cystic fibrosis patients to stop using inhaled corticosteroids

In comparison to cystic fibrosis (CF) patients who regularly use inhaled corticosteroid, those who did not use these drugs for six months exhibited no positive or negative effects in terms of major disease factors.

18 Jun 2006

AUA podium session on stone disease

2-phase randomized crossover study on a constant diet with calcium carbonate supplementation at 250 mg 4 times daily.

13 Jun 2006

Parkinson's patients stomach new drug better than conventional meds

Several studies conducted at Baylor College of Medicine (BCM) in Houston show that a new kind of orally disintegrating tablets provides improved symptom relief for patients with Parkinson's disease.

13 Jun 2006

Are we over-dosing on antibiotics?

Dutch researchers say that a three day course of antibiotics is just as effective as the usual seven to 10 days course when it comes to treating common pneumonia.

12 Jun 2006

When it comes to diabetes doctors failing to follow 'doctors orders'

According to the latest reports when it comes to diabetes and following doctors orders, doctors are failing their patients.

12 Jun 2006

New drug helps diabetics keep their sight

Trials of an experimental drug which helps slow down the loss of vision caused by diabetes have had very optimistic results.

12 Jun 2006

Microbes could represent the future of medicine

Not all bacteria are bad. In fact, beneficial microbes could represent the future of medicine, with the potential to treat a variety of diseases in humans and animals from diarrhea and eczema to gum disease and autoimmune disorders.

9 Jun 2006

What is the optimal duration of antibiotic therapy?

Taking antibiotics for three days is just as effective for community acquired pneumonia as continuing treatment for the recommended 7-10 days, finds a study in this week's British Medical Journal.

8 Jun 2006

Sunitinib shows promise in treating metastatic renal cell cancer

A new study suggests that sunitinib is a promising agent for treatment of metastatic renal cell cancer, currently a disease without highly effective treatment options, according to an article in the June 7 issue of the Journal of the American Medical Association.

7 Jun 2006